Intellia Therapeutics (NTLA) Reports Q1 Loss of $0.49/Share

Intellia Therapeutics (NASDAQ: NTLA) reported Q1 EPS of ($0.49), versus ($0.51) reported last year. Revenue for the quarter came in at $10.43 million, versus $7.47 million reported last year.

For earnings history and earnings-related data on Intellia Therapeutics (NTLA) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance
• Veeva Systems (VEEV) Tops Q1 EPS by 10c, Offers Guidance